Treatment of opioid-induced gut dysfunction

Expert Opinion on Investigational Drugs

Volumn 16, Issue 2, 2007, Pages 181-194

  Holzer, Peter ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Alvimopan; Constipation; Enteric nervous system; Intestinal peristalsis; N methylnaltrexone; Naloxone; Opiod induced bowel dysfunction; Opioid peptides; Peripherally restricted opioid receptor antagonists; Prokinetic effects

Indexed keywords

17 METHYLNALTREXONE; ALVIMOPAN; CERULETIDE; DEXLOXIGLUMIDE; DOMPERIDONE; ERYTHROMYCIN; FENTANYL; LAXATIVE; METOCLOPRAMIDE; MORPHINE; MU OPIATE RECEPTOR; NALMEFENE; NALOXONE; NARCOTIC ANALGESIC AGENT; NEOSTIGMINE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OPIATE ANTAGONIST; PLACEBO; PROKINETIC AGENT; RENZAPRIDE; TEGASEROD; TRAMADOL;

ABDOMINAL CRAMP; ABDOMINAL SURGERY; ANALGESIA; BLOOD BRAIN BARRIER; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE SEVERITY; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; ILEUS; INTESTINE MOTILITY; INTESTINE SECRETION; INTESTINE TRANSIT TIME; NAUSEA; NONHUMAN; ORTHOSTATIC HYPOTENSION; PAIN; PATIENT CONTROLLED ANALGESIA; PELVIS SURGERY; POSTOPERATIVE COMPLICATION; REPEATED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; STOMACH MOTILITY; VOMITING;

ANALGESICS, OPIOID; ANIMALS; DRUGS, INVESTIGATIONAL; GASTROINTESTINAL DISEASES; GASTROINTESTINAL MOTILITY; HUMANS; NARCOTIC ANTAGONISTS; RECEPTORS, OPIOID, MU;

EID: 33846782895     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.2.181     Document Type: Review

References (107)

1. KURZ A, SESSLER DI: Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs (2003) 63:649-671.
2. HOLZER P: Opioids and opioid receptors in the enteric nervous system: from a problem in opioid analgesia to a possible new prokinetic therapy in humans. Neurosci. Lett. (2004) 361:192-195.
3. DE PONTI F, GIARONI C, COSENTINO M, LECCHINI S, FRIGO G: Adrenergic mechanisms in the control of gastrointestinal motility: from basic science to clinical applications. Pharmacol. Ther. (1996) 69:59-78.
4. FRUHWALD S, HOLZER P, METZLER H: Intestinal motility disturbances in intensive care patients: pathogenesis and clinical impact. Intensive Care Med. (2006) (In Press).
5. KROMER W: Endogenous and exogenous opioids in the control of gastrointestinal motility and secretion. Pharmacol. Rev, (1988) 40:121-162.
6. DE LUCA A, COUPAR IM: Insights into opioid action in the intestinal tract. Pharmacol. Ther. (1996) 69:103-115.
7. CAMILLERI M: Alvimopan, a selective peripherally acting μ-opioid antagonist. Neurogastroenterol. Motil. (2004) 17:157-165.
8. SANGER GJ, TULADHAR BR: The role of endogenous opiates in the control of gastrointestinal motility: predictions from in vitro modelling. Neurogastroenterol. Motil. (2004) 16(Suppl. 2):38-45.
9. SANGER GJ, HOLZER P: Endogenous opioids and the gastrointestinal tract. Semin. Colon Rectal Surg. (2005) 16:197-199.
10. HOLZER P, SCHICHO R, HOLZER-PETSCHE U, LIPPE IT: The gut as a neurological organ. Wiener Klin. Wochenschr. (2001) 113:647-660.
11. BROOKES SJH: Classes of enteric nerve cells in the guinea-pig small intestine. Anat. Rec. (2001) 262:58-70.
12. FURNESS JB: The enteric nervous system. Blackwell Science, Oxford, UK (2006).
13. STERNINI C, PATIERNO S, SELMER IS, KIRCHGESSNER A: The opioid system in the gastrointestinal tract. Neurogastroenterol. Motil. (2004) 16(Suppl. 2):3-16.
14. COSTA M, BROOKES SJH, STEELE PA, GIBBINS I, BURCHER E, KANDIAH CJ: Neurochemical classification of myenteric neurons in the guinea-pig ileum. Neuroscience (1996) 75:949-967.
15. FURNESS JB: Types of neurons in the enteric nervous system. J. Auton. Nerv. Syst. (2000) 81:87-96.
16. STERNINI C, SPANN M, ANTON B et al.: Agonist-selective endocytosis of μ opioid receptor by neurons in vivo. Proc. Natl. Acad. Sci. USA (1996) 93:9241-9246.
17. BAGNOL D, MANSOUR A, AKIL H, WATSON SJ: Cellular localization and distribution of the cloned μ and κ opioid receptors in rat gastrointestinal tract. Neuroscience (1997) 81:579-591.
18. FICKEL J, BAGNOL D, WATSON SJ, AKIL H: Opioid receptor expression in the rat gastrointestinal tract: a quantitative study with comparison to the brain. Mol. Brain. Res. (1997) 46:1-8.
19. 2 receptor-mediated control of peristaltic propulsion in the guinea-pig small intestine in vitro. Neuropharmacology (1998) 37:131-138.
20. SHAHBAZIAN A, HEINEMANN A, SCHMIDHAMMER H, BEUBLER E, HOLZER-PETSCHE U, HOLZER P: Involvement of μ- and κ-, but not δ-, opioid receptors in the peristaltic motor depression caused by endogenous and exogenous opioids in the guinea-pig intestine. Br. J. Pharmacol. (2002) 135:741-750.
21. WOOD JD, GALLIGAN JJ: Function of opioids in the enteric nervous system. Neurogastroenterol. Motil. (2004) 16(Suppl. 2):17-28.
22. TONINI M, WATERMAN SA, CANDURA SM, COCCINI T, COSTA M: Sites of action of morphine on the ascending excitatory reflex in the guinea-pig small intestine. Neurosci. Lett. (1992) 144:195-198.
23. CALIGNANO A, MONCADA S, DI ROSA M: Endogenous nitric oxide modulates morphine-induced constipation. Biochem. Biophys. Res. Commun. (1991) 181:889-893.
24. LENARD L, HALMAI V, BARTHO L: Morphine contracts the guinea pig ileal circular muscle by interfering with a nitric oxide mediated tonic inhibition. Digestion (1999) 60:562-566.
25. HIRNING LD, PORRECA F, BURKS TF: μ, but not κ, opioid agonists induce contractions of the canine small intestine ex vivo. Eur. J. Pharmacol. (1985) 109:49-54.
26. POONYACHOTI S, PORTOGHESE PS, BROWN DR: Characterization of opioid receptors modulating neurogenic contractions of circular muscle from porcine ileum and evidence that δ- and κ-opioid receptors are coexpressed in myenteric neurons. J. Pharmacol. Exp. Ther. (2001) 297:69-77.
27. SARNA SK, LANG IM: Dose- and time-dependent biphasic response to morphine on intestinal migrating myoelectric complex. J. Pharmacol. Exp. Ther. (1985) 234:814-820.
28. KAUFMAN PN, KREVSKY B, MALMUD LS et al.: Role of opiate receptors in the regulation of colonic transit. Gastroenterology (1988) 94:1351-1356.
29. DELGADO-AROS S, CHIAL HJ, CAMILLERI M et al,: Effects of a κ-opioid agonist, asimadoline, on satiation and GI motor and sensory functions in humans. Am. J. Physiol. (2003) 284:G558-G566.
30. STACHER G, STEINRINGER H, SCHNEIDER C et al.: Effects ofthe prodrug loperamide oxide, loperamide, and placebo on jejunal motor activity. Dig. Dis. Sci. (1992) 37:198-204.
31. SUN WM, READ NW, VERLINDEN M: Effects of loperamide oxide on gastrointestinal transit time and anorectal function in patients with chronic diarrhoea and faecal incontinence. Scand, J. Gastroenterol. (1997) 32:34-38.
32. BEUBLER E, LEMBECK F: Inhibition of stimulated fluid secretion in the rat small and large intestine by opiate agonists. Naunyn-Schmiedeberg's Arch. Pharmacol. (1979) 306:113-118.
33. TURNBERG LA: Antisecretory activity of opiates in vitro and in vivo in man. Scand. J. Gastroenterol. (1983) 84:79-83.
34. BAUER AJ, SARR MG, SZURSZEWSKI JH: Opioids inhibit neuromuscular transmission in circular muscle of human and baboon jejunum. Gastroenterology (1991) 101:970-976.
35. CHAMOUARD P, KLEIN A, MARTIN E, ADLOFF M, ANGEL F: Regulatory role of enteric κ opioid receptors in human colonic motility. Life Sci. (1993) 53:1149-1156.
36. KOJIMA Y, TAKAHASHI T, FUJINA M, OWYANG C: Inhibition of cholinergic transmission by opiates in ileal myenteric plexus is mediated by κ receptor. Involvement of regulatory inhibitory G protein and calcium N-channels. J. Pharmacol. Exp. Ther. (1994) 268:965-970.
37. DONNERER J, HOLZER P, LEMBECK F: Release of dynorphin, somatostatin and substance P from the vascularly perfused small intestine of the guinea-pig during peristalsis. Br, J. Pharmacol. (1984) 83:919-925.
38. COSENTINO M, MARINO F, DE PONTI F et al.: Tonic modulation of neurotransmitter release in the guinea-pig myenteric plexus: effect of μ and κ opioid receptor blockade and of chronic sympathetic denervation. Neurosci. Lett. (1995) 194:185-188.
39. YUAN CS, FOSS JF, MOSS J: Effects of methylnaltrexone on morphine-induced inhibition of contraction in isolated guinea-pig ileum and human intestine. Eur. J. Pharmacol. (1995) 276:107-111.
40. CAMILLERI M, MALAGELADA JR, STANGHELLINI V, ZINSMEISTER AR, KAO PC, LI CH: Dose-related effects of synthetic human β-endorphin and naloxone on fed gastrointestinal motility. Am. J. Physiol. (1986) 251:147-154.
41. YUAN CS, DOSHAN H, CHARNEY MR et al.: Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans. J. Clin. Pharmacol. (2005) 45:538-546.
42. GONENNE J, CAMILLERI M, FERBER I et al.: Effect of alvimopan and codeine on gastrointestinal transit: a randomized controlled study. Clin. Gastroenterol. Hepatol. (2005) 3:784-791.
43. SCHAUMANN O: Pain, the protective system and combinations with morphine-like effect. Wiener Med. Wochenschr. (1959) 109:78-81.
44. HUGHES J, SMITH TW, KOSTERLITZ HW, FOTHERGILL LA, MORGAN BA, MORRIS HR: Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature (1975) 258:577-580.
45. CLARK SJ, SMITH TW. The release of met-enkephalin from the guinea-pig ileum at rest mid during peristaltic activity. Life Sci. (1983) 33(Suppl. 1):465-468.
46. VAN NUETEN JM, JANSSEN PAJ, FONTAINE J: Unexpected reversal effects of naloxone on the guinea-pig ileum. Life Sci. (1976) 18:803-810.
47. KROMER W, PRETZLAFF W: In vitro evidence for the participation of intestinal opioids in the control of peristalsis in the guinea-pig small intestine. Naunyn-Schmiedeberg's Arch. Pharmacol. (1979) 309:153-157.
48. KROMER W, PRETZLAFF W, WOINOFF R: Opioids modulate periodicity rather than efficacy of peristaltic waves in the guinea-pig ileum in vitro. Life Sci. (1980) 26:1857-1865.
49. BROWN NJ, RUMSEY RDE, BOGENTOFT C, READ NW. The effect of an opiate receptor antagonist on the ileal brake mechanism in the rat. Pharmacology (1993) 47:230-236.
50. MILLION M, FIORAMONTI J, ZAJAC JM, BUENO L: Effects of neuropeptide FF on intestinal motility and temperature changes induced by endotoxin and platelet activating factor. Eur. J. Pharmacol. (1997) 334:67-73.
51. DE WINTER BY, BOECKXSTAENS GE, DE MAN JG, MOREELS TG, HERMAN AG, PELCKMANS PA: Effects of μ- and κ-opioid receptors on postoperative ileus in rats. Eur. J. Pharmacol. (1997) 339:63-67.
52. YATES DA, SANTOS J, SÖDERHOLM JD, PERDUE MH: Adaptation of stress-induced mucosal pathophysiology in rat colon involves opioid pathways. Am. J. Physiol. (2001) 281:G124-G128.
53. PUIG MM, POL O: Peripheral effects of opioids in a model of chronic intestinal inflammation in mice. J. Pharmacol. Exp. Ther. (1998) 287:1068-1075.
54. POL O, ALAMEDA F, PUIG MM: Inflammation enhances μ-opioid receptor transcription and expression in mice intestine. Mol. Pharmacol. (2001) 60:894-899.
55. YOSHIDA S, OHTA J, YAMASAKI K et al.: Effect of surgical stress on endogenous morphine and cytokine levels in the plasma after laparoscopoic or open cholecystectomy. Surg. Endosc. (2000) 14:137-140.
56. KREEK MJ, SCHAEFER RA, HAHN EF, FISHMAN J: Naloxone, a specific opioid antagonist, reverses chronic idiopathic constipation. Lancet (1983) 1:261-262.
57. SCHANG JC, DEVROEDE G: Beneficial effects of naloxone in a patient with intestinal pseudoobstruction. Am. J. Gastroenterol. (1985) 80:407-411.
58. HAWKES ND, RHODES J, EVANS BK, RHODES P, HAWTHORNE AB, THOMAS GA: Naloxone treatment for irritable bowel syndrome - a randomized controlled trial with an oral formulation. Aliment. Pharmacol. Ther. (2002) 16:1649-1654.
59. 3 receptor antagonism: evidence for heterogeneous efficacy among different antagonists in guinea-pigs. J. Pharm. Pharmacol. (1994) 46:666-670.
60. BARTHO L, HOLZER P, LEMBECK F: Is ganglionic transmission through nicotinic receptors essential for the peristaltic reflex in guinea-pig ileum? Neurapharmacology (1987) 26:1663-1666.
61. HEINEMANN A, HOLZER P: Stimulant action of pituitary adenylate cyclase-activating peptide on normal and drug-compromised peristalsis in the guinea-pig intestine. Br. J. Pharmacol. (1999) 127:763-771.
62. MANARA L, BIANCHETTI A: The central and peripheral influences of opioids on gastrointestinal propulsion, Ann. Rev. Pharmacol. Toxicol. (1985) 25:249-273.
63. MATHESON AJ, NOBLE S: Racecadotril. Drugs (2000) 59:829-835.
64. SCHWARTZ JC: Racecadotril: a new approach to the treatment of diarrhoea. Int. J. Antimicrob. Agents (2000) 14:75-79.
65. SALAZAR-LINDO E, SANTISTEBAN-PONCE J, CHEA-WOO E, GUTIERREZ M: Racecadotril in the treatment of acute watery diarrhea in children. N. Engl. J. Med. (2000) 343:463-467.
66. PRADO D, GLOBAL ADULT RACECADOTRIL STUDY GROUP: A multinational comparison of racecadotril and loperamide in the treatment of acute watery diarrhoea in adults. Scand J. Gastroenterol. (2002) 37:656-661.
67. FOSS JF: A review of the potential role of methylnaltrexone in opioid bowel dysfunction. Am. J, Surg. (2001) 182(Suppl.): 19S-26S.
68. YUAN CS, FOSS JE O'CONNOR M, MOSS J, ROIZEN MF: Gut motility and transit changes in patients receiving long-term methadone maintenance. J. Clin. Pharmacol. (1998) 38:931-935.
69. MANARA L, BIANCHI G, FERRETTI P, TAVANI A: Inhibition of gastrointestinal transit by morphine in rats results primarily from direct drug action on gut opioid sites. J. Pharmacol. Exp. Ther. (1986) 237:945-949.
70. BIANCHI G, FIOCCHI R, TAVANI A, MANARA L: Quaternary narcotic antagonists' relative ability to prevent antinociception and gastrointestinal transit inhibition in inorphine-treated rats as an index of peripheral selectivity. Life Sci. (1982) 30:1875-1883.
71. RUSSELL J, BASS P, GOLDBERG LI, SCHUSTER CR, MERZ H: Antagonism of gut, but not central effects of morphine with quaternary narcotic antagonists. Eur. J. Pharmacol. (1982) 78:255-261.
72. CALI RL, MEADE PG, SWANSON MS, FREEMAN C: Effect of morphine and incision length on bowel function after colectomy. Dis. Colon Rectum (2000) 43:163-168.
73. LUCKEY A, LIVINGSTON E, TACHE Y: Mechanisms and treatment of postoperative ileus. Arch. Surg. (2003) 138:206-214.
74. BAUER AJ, BOECKXSTAENS GE: Mechanisms of postoperative ileus. Neurogastroenterol. Motil. (2004) 16(Suppl. 2):54-60.
75. HERNDON CM, JACKSON KC, HALLIN PA: Management of opioid-induced gastrointestinal effects in patients receiving palliative care. Pharmacotherapy (2002) 22:240-250.
76. GALLIGAN JJ, VANNER S: Basic and clinical pharmacology of new motility promoting agents. Neurogastroenterol. Motil. (2005) 17:643-653.
77. DONNER B, ZENZ M, STRUMPF M, RABER M: Long-term treatment of cancer pain with transdermal fentanyl. J. Pain Symptom Manage. (1998) 15:168-175.
78. ALLAN L, HAYS H, JENSEN NH et al.: Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. Br. Med. J. (2001) 322:1154-1158.
79. GREENWOOD-VAN MEERVELD B, GARDNER CJ, LITTLE PJ, HICKS GA, DEHAVEN-HUDKINS DL: Preclinical studies of opioids and opioid antagonists on gastrointestinal function. Neurogastroenterol. Motil. (2004) 16(Suppl. 2):46-53.
80. JURNA I, KAISER R, KRETZ O, BALDAUF J: Oral naloxone reduces constipation but not antinociception from oral morphine in the rat. Neurosci. Lett. (1992) 142:62-64.
81. SYKES NP: An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliat. Med. (1996) 10:135-144.
82. MEISSNER W, SCHMIDT U, HARTMANN M, KATH R, REINHART K: Oral naloxone reverses opioid-associated constipation. Pain (2000) 84:105-109.
83. CHESKIN LJ, CHAMI TN, JOHNSON RE, JAFFE JH: Assessment of nalmefene glucuronide as a selective gut opioid antagonist. Drug Alcohol Depend. (1995) 39:151-154.
84. YUAN CS, ISRAEL RJ: Methylnaltrexone, a novel peripheral opioid receptor antagonist for the treatment of opioid side effects. Expert Opin. Investig. Drugs (2006) 15(5):541-552.
85. YUAN CS, FOSS JF, OSINSKI J, TOLEDANO A, ROIZEN MF, MOSS J: The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time. Clin. Pharmacol. Ther. (1997) 61:467-475.
86. YUAN CS, FOSS JF, O'CONNOR M, TOLEDANO A, ROIZEN MF, MOSS J: Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: a double-blind randomized placebo-controlled trial. Clin. Pharmacol. Ther. (1996) 59:469-475.
87. KOTAKE AN, KUWAHARA SK, BURTON E, McCoy CE, GOLDBERG LI: Variations in demethylation of N-methyinaltrexone in mice, rats, dogs, and humans. Xenobiotica (1989) 19:1247-1254.
88. FOSS JF, O'CONNOR ME, YUAN CS, MURPHY M, MOSS J, ROIZEN MF: Safety and tolerance of methylnaltrexone in healthy humans: a randomized, placebo-controlled, intravenous, ascending-dose, pharmacokinetic study. J, Clin. Pharmacol. (1997) 37:25-30.
89. MURPHY DB, SUTTON JA, PRESCOTT LF, MURPHY MB: Opioid-induced delay in gastric emptying: a peripheral mechanism in humans. Anesthesiology (1997) 87:765-770.
90. YUAN CS, WEI G, FOSS JF, O'CONNOR M, KARRISON T, OSINSKI J: Effects of subcutaneous methyinaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial. J. Pharmacol. Exp. Ther. (2002) 300:118-123.
91. YUAN CS, FOSS JF, O'CONNOR M et al.: Effects of enteric-coated methylnaltrexone in preventing opioid-induced delay in oral-cecal transit time. Clin. Pharmacol. Ther. (2000) 67:398-404.
92. YUAN CS, FOSS JF, O'CONNOR M et al.: Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized, controlled trial. JAMA (2000) 283:367-372.
93. YUAN CS, FOSS JF: Oral methylnaltrexone for opioid-induced constipation. JAMA (2000) 284:1383-1384.
94. FUKUDA H, SUENAGA K, TSUCHIDA D et al.: The selective μ opioid receptor antagonist, alvimopan, improves delayed GI transit of postoperative ileus in rats. Brain Res. (2006) 1102:63-70.
95. SCHMIDT WK: Alvimopan (ADL 8-2698) is a novel peripheral opioid antagonist. Am. J, Surg. (2001) 182:27S-38S (Supplement),
96. LESLIE JB: Alvimopan for the management of postoperative ileus. Ann. Pharmacother. (2005) 39:1502-1510.
97. NEARY P, DELANEY CP: Alvimopan. Expert Opin. Investig. Drugs (2005) 14(4):479-488.
98. ZIMMERMAN DM, GIDDA JS, CANTRELL BE, SCHOEPP DD, JOHNSON BG, LEANDER JD: Discovery of a potent, peripherally selective trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine opioid antagonist for the treatment of gastrointestinal motility disorders. J. Med. Chem. (1994) 37:2262-2265.
99. LIU SS, HODGSON PS, CARPENTER RL, FRICKE JR: ADL 8-2698, a trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous morphine without affecting analgesia. Clin. Pharmacol. Ther (2001) 69:66-71.
100. PAULSON DM, KENNEDY DT, DONOVICK RA et al.: Alvimopan: an oral, peripherally acting, μ-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction - a 21-day treatment-randomized clinical trial. J. Pain (2005) 6:184-192.
101. TAGUCHI A, SHARMAN, SALEEM RM et al.: Selective postoperative inhibition of gastrointestinal opioid receptors. N. Engl. J. Med. (2001) 345:935-940.
102. WOLFF BG, MICHELASSI F, GERKIN TM et al.; ALVIMOPAN POSTOPERATIVE ILEUS STUDY GROUP: Alvimopan, a novel peripherally acting μ opioid antagonist. Results of a multicenter, randomized, double-blind, placebo-controlled, Phase III trial of major abdominal surgery and postoperative ileus. Ann. Surg. (2004) 240:728-735.
103. DELANEY CP, WEESE JL, HYMAN NH et al.; ALVIMOPAN POSTOPERATIVE ILEUS STUDY GROUP: Phase III trial of alvimopan, a novel, peripherally acting, μ opioid antagonist, for postoperative ileus after major abdominal surgery. Dis. Colon Rectum (2005) 48:1114-1125.
104. HERZOG TJ, COLEMAN RL, GUERRIERI JP et al: A double-blind, randomized, placebo-controlled Phase III study of the safety of alvimopan in patients who undergo simple total abdominal hysterectomy. Am. J. Obstet. Gynecol. (2006) 195:445-453.
105. VISCUSI ER, GOLDSTEIN S, WITKOWSKI T et al,: Alvimopan, a peripherally acting μ-opioid receptor antagonist, compared with placebo in postoperative ileus after major abdominal surgery: results ofa randomized, double-blind, controlled study. Surg. Endosc. (2006) 20:64-70.
106. TAN EK, CORNISH J, DARZI AW, TEKKIS PP: Meta-analysis: alvimopan vs. placebo in the treatment of post-operative ileus. Aliment. Pharmacol. Ther. (2006) (In Press).
107. GARNETT W, KELLEHER DL, HICKMOTT F et al.: Alvimopan (ALV) shortens whole bowel transit time in adults with chronic constipation (CC). Gastroenterology (2004) 126:A643.